Oestrogen induced downregulation of TFPI expression is mediated by ERα

Thrombosis Research

Volumn 134, Issue 1, 2014, Pages 138-143

  Ali, Huda Omar ^a,b,c   Stavik, Benedicte ^a,b   Dørum, Elisabeth ^a,b   Iversen, Nina ^a   Sandset, Per Morten ^a,b,c   Skretting, Grethe ^a,b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

Author keywords

ER ; fulvestrant; FXa; oestrogen; raloxifene; TFPI

Indexed keywords

BLOOD CLOTTING FACTOR 10A; CYCLOHEXIMIDE; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ETHINYLESTRADIOL; FULVESTRANT; MESSENGER RNA; RALOXIFENE; SMALL INTERFERING RNA; TISSUE FACTOR PATHWAY INHIBITOR; LIPOPROTEIN; LIPOPROTEIN-ASSOCIATED COAGULATION INHIBITOR; TUMOR MARKER;

ARTICLE; BREAST CANCER CELL LINE; CONTROLLED STUDY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ESTROGEN ACTIVITY; GENE EXPRESSION; GENE SILENCING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; INCUBATION TIME; MCF 7 CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ADENOCARCINOMA; BIOSYNTHESIS; BLOOD; BREAST TUMOR; DRUG EFFECTS; FEMALE; GENETICS; METABOLISM; THROMBOSIS;

ADENOCARCINOMA; BREAST NEOPLASMS; DOWN-REGULATION; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ETHINYL ESTRADIOL; FEMALE; HUMANS; LIPOPROTEINS; MCF-7 CELLS; THROMBOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84902535994     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2014.04.004     Document Type: Article

References (44)

1. H.R. Buller, F.F. van Doormaal, G.L. van Sluis, and P.W. Kamphuisen Cancer and thrombosis: from molecular mechanisms to clinical presentations J Thromb Haemost 5 Suppl. 1 2007 246 254
2. E.J. Folkerd, and M. Dowsett Influence of sex hormones on cancer progression J Clin Oncol 28 2010 4038 4044
3. J.M. Renoir, V. Marsaud, and G. Lazennec Estrogen receptor signaling as a target for novel breast cancer therapeutics Biochem Pharmacol 85 2013 449 465
4. P. Ascenzi, A. Bocedi, and M. Marino Structure-function relationship of estrogen receptor alpha and beta: impact on human health Mol Aspects Med 27 2006 299 402
5. S. Ali, and R.C. Coombes Estrogen receptor alpha in human breast cancer: occurrence and significance J Mammary Gland Biol Neoplasia 5 2000 271 281
6. N. Heldring, A. Pike, S. Andersson, J. Matthews, G. Cheng, and J. Hartman et al. Estrogen receptors: how do they signal and what are their targets Physiol Rev 87 2007 905 931
7. S.E. Fawell, R. White, S. Hoare, M. Sydenham, M. Page, and M.G. Parker Inhibition of estrogen receptor-DNA binding by the "pure" antiestrogen ICI 164,384 appears to be mediated by impaired receptor dimerization Proc Natl Acad Sci U S A 87 1990 6883 6887
8. J.F. Robertson, S.E. Come, S.E. Jones, L. Beex, M. Kaufmann, and A. Makris et al. Endocrine treatment options for advanced breast cancer-the role of fulvestrant Eur J Cancer 41 2005 346 356
9. J.E. Rossouw, G.L. Anderson, R.L. Prentice, A.Z. LaCroix, C. Kooperberg, and M.L. Stefanick et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial JAMA 288 2002 321 333
10. A.L. Eilertsen, L. Sandvik, M.C. Mowinckel, T.O. Andersen, E. Qvigstad, and P.M. Sandset Differential effects of conventional and low dose oral hormone therapy (HT), tibolone, and raloxifene on coagulation and fibrinolysis Thromb Res 120 2007 371 379
11. G.M. Harris, C.L. Stendt, B.J. Vollenhoven, T.E. Gan, and P.G. Tipping Decreased plasma tissue factor pathway inhibitor in women taking combined oral contraceptives Am J Hematol 60 1999 175 180
12. A. Dahm, Vlieg A. Van Hylckama, B. Bendz, F. Rosendaal, R.M. Bertina, and P.M. Sandset Low levels of tissue factor pathway inhibitor (TFPI) increase the risk of venous thrombosis Blood 101 2003 4387 4392
13. P.E. Morange, C. Simon, M.C. Alessi, G. Luc, D. Arveiler, and J. Ferrieres et al. Endothelial cell markers and the risk of coronary heart disease: the Prospective Epidemiological Study of Myocardial Infarction (PRIME) study Circulation 109 2004 1343 1348
14. M.S. Bajaj, M.N. Kuppuswamy, H. Saito, S.G. Spitzer, and S.P. Bajaj Cultured normal human hepatocytes do not synthesize lipoprotein-associated coagulation inhibitor: evidence that endothelium is the principal site of its synthesis Proc Natl Acad Sci U S A 87 1990 8869 8873
15. G.C. Price, S.A. Thompson, and P.C. Kam Tissue factor and tissue factor pathway inhibitor Anaesthesia 59 2004 483 492
16. M.A. Kurer Protein and mRNA expression of tissue factor pathway inhibitor-1 (TFPI-1) in breast, pancreatic and colorectal cancer cells Mol Biol Rep 34 2007 221 224
17. E. Sierko, M.Z. Wojtukiewicz, L. Zimnoch, and W. Kisiel Expression of tissue factor pathway inhibitor (TFPI) in human breast and colon cancer tissue Thromb Haemost 103 2010 198 204
18. B. Stavik, M. Tinholt, M. Sletten, G. Skretting, P.M. Sandset, and N. Iversen TFPIalpha and TFPIbeta are expressed at the surface of breast cancer cells and inhibit TF-FVIIa activity J Hematol Oncol 6 2013 5
19. N. Iversen, A.K. Lindahl, and U. Abildgaard Elevated TFPI in malignant disease: relation to cancer type and hypercoagulation Br J Haematol 102 1998 889 895
20. A.E. Dahm, N. Iversen, B. Birkenes, A.H. Ree, and P.M. Sandset Estrogens, selective estrogen receptor modulators, and a selective estrogen receptor down-regulator inhibit endothelial production of tissue factor pathway inhibitor 1 BMC Cardiovasc Disord 6 2006 40
21. A.S. Bilsel, N. Onaran, H. Moini, and K. Emerk Long-term effect of 17beta-estradiol and thrombin on tissue factor pathway inhibitor release from HUVEC Thromb Res 99 2000 173 178
22. R.A. Shirk, Z. Zhang, and R.C. Winneker Differential effects of estrogens and progestins on the anticoagulant tissue factor pathway inhibitor in the rat J Steroid Biochem Mol Biol 94 2005 361 368
23. J.F. Brosnan, B.L. Sheppard, L.A. Kelly, J.J. O'Leary, and L.A. Norris Norethisterone acetate alters coagulation gene expression in vitro in human cell culture Thromb Res 131 2013 72 77
24. B. Toth, G. Saadat, A. Geller, C. Scholz, S. Schulze, and K. Friese et al. Human umbilical vascular endothelial cells express estrogen receptor beta (ERbeta) and progesterone receptor A (PR-A), but not ERalpha and PR-B Histochem Cell Biol 130 2008 399 405
25. L.C. Folmar, M. Hemmer, N.D. Denslow, K. Kroll, J. Chen, and A. Cheek et al. A comparison of the estrogenic potencies of estradiol, ethynylestradiol, diethylstilbestrol, nonylphenol and methoxychlor in vivo and in vitro Aquat Biol 60 2002 101 110
26. S. Ali, and R.C. Coombes Endocrine-responsive breast cancer and strategies for combating resistance Nat Rev Cancer 2 2002 101 112
27. F. Novelli, M. Milella, E. Melucci, A. Di Benedetto, I. Sperduti, and R. Perrone-Donnorso et al. A divergent role for estrogen receptor-beta in node-positive and node-negative breast cancer classified according to molecular subtypes: an observational prospective study Breast Cancer Res 10 2008 R74
28. N. Honma, R. Horii, T. Iwase, S. Saji, M. Younes, and K. Takubo et al. Clinical importance of estrogen receptor-beta evaluation in breast cancer patients treated with adjuvant tamoxifen therapy J Clin Oncol 26 2008 3727 3734
29. G.P. Skliris, E. Leygue, L. Curtis-Snell, P.H. Watson, and L.C. Murphy Expression of oestrogen receptor-beta in oestrogen receptor-alpha negative human breast tumours Br J Cancer 95 2006 616 626
30. T. Ballantyne, Q. Du, S. Jovanovic, A. Neemo, R. Holmes, and S. Sinha et al. Testosterone protects female embryonic heart H9c2 cells against severe metabolic stress by activating estrogen receptors and up-regulating IES SUR2B Int J Biochem Cell Biol 45 2013 283 291
31. S.R. Goldstein, C.S. Duvernoy, J. Calaf, J.D. Adachi, J.L. Mershon, and S.A. Dowsett et al. Raloxifene use in clinical practice: efficacy and safety Menopause 16 2009 413 421
32. A.M. Wardley Fulvestrant: a review of its development, pre-clinical and clinical data Int J Clin Pract 56 2002 305 309
33. S. Yeh, H. Miyamoto, H. Shima, and C. Chang From estrogen to androgen receptor: a new pathway for sex hormones in prostate Proc Natl Acad Sci U S A 95 1998 5527 5532
34. M. Saceda, R.K. Lindsey, H. Solomon, S.V. Angeloni, and M.B. Martin Estradiol regulates estrogen receptor mRNA stability J Steroid Biochem Mol Biol 66 1998 113 120
35. M. Ohh, and F. Takei Regulation of ICAM-1 mRNA stability by cycloheximide: role of serine/threonine phosphorylation and protein synthesis J Cell Biochem 59 1995 202 213
36. F. Busi, and T. Cresteil CYP3A5 mRNA degradation by nonsense-mediated mRNA decay Mol Pharmacol 68 2005 808 815
37. A.K. Lindahl, U. Abildgaard, and R. Staalesen The anticoagulant effect in heparinized blood and plasma resulting from interactions with extrinsic pathway inhibitor Thromb Res 64 1991 155 168
38. X. Jiang, S. Zhu, T.S. Panetti, and M.E. Bromberg Formation of tissue factor-factor VIIa-factor Xa complex induces activation of the mTOR pathway which regulates migration of human breast cancer cells Thromb Haemost 100 2008 127 133
39. Z. Chen, and R. Sager Differential expression of human tissue factor in normal mammary epithelial cells and in carcinomas Mol Med 1 1995 153 160
40. M. Matan, E. Axelman, B. Brenner, and Y. Nadir Heparanase procoagulant activity is elevated in women using oral contraceptives Hum Reprod 28 2013 2372 2380
41. Y. Nadir, and B. Brenner Heparanase coagulation and cancer progression Best Pract Res Clin Haematol 22 2009 85 92
42. T.B. Bevers Raloxifene and the prevention of breast cancer Expert Opin Pharmacother 7 2006 2301 2307
43. B. Stavik, G. Skretting, M. Sletten, P.M. Sandset, and N. Iversen Overexpression of both TFPIalpha and TFPIbeta induces apoptosis and expression of genes involved in the death receptor pathway in breast cancer cells Mol Carcinog 49 2010 951 963
44. B. Stavik, G. Skretting, H.C. Aasheim, M. Tinholt, L. Zernichow, and M. Sletten et al. Downregulation of TFPI in breast cancer cells induces tyrosine phosphorylation signaling and increases metastatic growth by stimulating cell motility BMC Cancer 11 2011 357